Pharvaris is a clinical-stage biopharmaceutical company developing oral therapies for hereditary angioedema (HAE), a rare genetic swelling disorder. Its pipeline centers on bradykinin B2 receptor antagonists intended as alternatives to injectable treatments. The company focuses on patients and clinicians seeking convenient oral options for HAE prophylaxis and acute treatment.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -45.5 | — |
| Q3 2025 | 0 | — | -37.1 | — |
| Q4 2025 | 0 | — | -46.7 | — |
| Q1 2026 | 0 | — | -39.2 | — |
| Q2 2026 | 0 | — | -47.8 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Immunome, Inc. (IMNM), Trump Media & Technology Group Corp. (DJT), nLIGHT, Inc. (LASR), eToro Group Ltd. (ETOR), SolarEdge Technologies, Inc. (SEDG), Plug Power Inc. (PLUG)